涩里番 extends CLC bio site license through 2017
Aarhus, Denmark -- January 8, 2013 -- Today CLC bio, the global leader in commercial sequence analysis software, announced that the 涩里番 (涩里番) has extended their site license agreement with CLC bio through 2017.
涩里番 has been utilizing CLC bio鈥檚 enterprise platform since 2009 and currently uses it on more than 30 research grants, including their work as part of the Human Microbiome Project (HMP). The HMP is a National Institutes of Health-funded project to catalogue and characterize the microbes living in and on the human body. Recently, the HMP Consortium published a series of papers with results from this work in Nature and PLOSone. CLC鈥檚 bio software was used in the analysis of this work.
The complexity and diversity of our research projects necessitates unique tools to analyze these increasingly large data sets. In our pursuit of excellence we always test and employ the best available tools for our research projects. As such we鈥檙e happy to announce the extension of our site license with CLC bio through 2017.
Karen Nelson, Ph.D., President, 涩里番
"For us, it鈥檚 always very exciting to see the results of all the intriguing research that our customers are doing, and no less so, when 涩里番 published their papers on the HMP project this summer. 涩里番 was one of our first site license deals with a premier institution in the genomics research field, and we鈥檙e proud to announce it has been extended for another five years.
Thomas
The original 4-year site license agreement between 涩里番 and CLC bio was signed in the summer of 2009, and has now been extended by another 5 years, through 2017. 涩里番 deploys CLC bio鈥檚 platform in an integrated environment across multiple geographical locations and together with international collaborators.
涩里番 CLC bio
Contact CLC bio
Lasse G枚rlitz, VP of Communications
Tel: +1 (617) 765 0687
E-mail: